Potential novel role of asthma biologics as rescue therapy in the intensive care unit for life-threatening asthma exacerbations: a systematic review
Monaldi Archives for Chest Disease · 2025
DOI: 10.4081/monaldi.2025.3319 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Monaldi Archives for Chest Disease, 2025. Verfasst von Lorenzo Carriera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Surgery, Catholic University of Sacred Heart, Rome. Hauptthemen laut MEDLINE: Asthma, Biological Products, Anti-Asthmatic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Intensivpflege
Abstract (Originalsprache)
Severe asthma exacerbations have high morbidity and mortality. The management can be challenging, and the optimal strategy for patients admitted to the intensive care unit (ICU) with life-threatening and near-fatal asthma has not been fully defined. An interesting area of research is represented by the rescue or compassionate use of biological drugs when all treatments fail, including advanced interventions such as extracorporeal membrane oxygenation. This systematic review analyzes the cases described in the literature and discusses characteristics, treatments, and outcomes of patients who received asthma-approved monoclonal antibodies as rescue therapy following admission to the ICU due to near-fatal asthma exacerbations or status asthmaticus refractory to conventional treatments. A total of 14 studies (13 case reports and 1 case series) were included according to the prespecified inclusion and exclusion criteria. Various monoclonal antibodies were administered, most commonly benralizumab and omalizumab. Treatment was generally initiated within the first week of ICU admission, with nearly half of the patients receiving therapy within 5 days. Further research, including randomized controlled trials, is required to assess if this therapeutic option impacts ICU outcomes, which specific biologics could be used, and their eventual optimal timing and dosage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Surgery, Catholic University of Sacred Heart, Rome.
- San Carlo di Nancy Hospital, Rome.
- Pulmonology Department, ASST Spedali Civili, Brescia.
- Pulmonology Division, Department of Neurosciences, Sense Organs and Thorax, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome.
- Pulmonology Division, San Filippo Neri Hospital, Rome; UniCamillus, Saint Camillus International University of Health Sciences, Rome.
Zitieren
APA
Carriera, L., Mari, P. V., Barone, R., Ielo, S., Cataldo, E., Di Tomasso, M., Bezzi, M., Smargiassi, A., Inchingolo, R., & Coppola, A. (2025). Potential novel role of asthma biologics as rescue therapy in the intensive care unit for life-threatening asthma exacerbations: a systematic review. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2025.3319
Vancouver
Carriera L, Mari PV, Barone R, Ielo S, Cataldo E, Di Tomasso M, et al. Potential novel role of asthma biologics as rescue therapy in the intensive care unit for life-threatening asthma exacerbations: a systematic review. Monaldi Archives for Chest Disease. 2025. doi:10.4081/monaldi.2025.3319
BibTeX
@article{Carriera2025,
author = {Carriera, Lorenzo and Mari, Pier Valerio and Barone, Roberto and Ielo, Simone and Cataldo, Emanuele and Di Tomasso, Michela and Bezzi, Michela and Smargiassi, Andrea and Inchingolo, Riccardo and Coppola, Angelo},
title = {Potential novel role of asthma biologics as rescue therapy in the intensive care unit for life-threatening asthma exacerbations: a systematic review},
journal = {Monaldi Archives for Chest Disease},
year = {2025},
doi = {10.4081/monaldi.2025.3319}
}
EUVIMED